MHC-matched parthenogenetic embryonic stem cells created

New strategy could make cells better transplant candidates

Written byCathy Tran
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share
Researchers have created major histocompatible complex (MHC)-matched parthenogenetic embryonic stem (pES) cells in mice that successfully engraft in an immunocompetent system, according to a report in Science. The work is a "tremendous advance," Kent Vrana at Pennsylvania State University told The Scientist. Vrana, who was not involved in the study, explained that the successful transplantation of pES cells had previously only been accomplished in immunodeficient animals. This is the first report to assess the MHC regions of pES cells, study author George Daley at the Children's Hospital Boston and Harvard Stem Cell Institute told The Scientist. Daley and his team selected for cells that contained heterozygous MHC genes to match the egg donor. MHC mismatch is a major reason for graft rejection, particularly in bone marrow transplant.The team, led by Kitai Kim at the Children's Hospital Boston and Harvard Medical School, developed embryonic stem cells from an unfertilized embryo through parthenogenesis. The researchers inhibited mouse oocytes at the first and second meiotic divisions and found that after recombination, up to 81% of the genome was perfectly matched to the egg donor. That number is "a very promising surprise," Jose Cibelli at Michigan State University, who was not part of the study, told The Scientist.To test compatibility, the researchers cultured and transplanted the MHC-matched pES cells into their respective female mice donors for up to three months. The protein analyses of tissues provided what Cibelli considers to be "proof of the principle that pES cells can be suitable transplant material." Teratoma tumor formation, which indicates an acceptance of the transplant, appeared in 100% of the immunocompetent mice.The finding adds to the appeal of using parthenogenetic cells, which has been demonstrated to be a more efficient method of creating ES cells. Kim told The Scientist that his success rate of generating ES cells is almost 70% through parthenogenesis but less than 1% through somatic cell nuclear transfer (SCNT).Parthenogenesis also presents "less severe ethical problems," said Azim Surani at the University of Cambridge, who was not part of the research team. He explained that "parthenogenetic embryos cannot develop into full organisms because you need both parental genomes for normal development. That takes away one key objection that people have."Study of parthenogenetic embryonic stem cells has not been a popular approach because most people believe SCNT is the more rationale method since it uses the exact nuclei from the donor, but the new finding highlights the promise of using parthenogenesis, Cibelli said. Vrana agreed, adding that "we should be exploring the utility of all tools until we find the right one."Surani said the next step would be to examine how the MHC-matched pES cells compare with ES cells from fertilized eggs. He and his colleagues previously reported that pES cells are "quite good" at differentiating into neurons but not into muscle tissues. How these findings would map onto MHC-matched pES cells is not yet clear. To address the concern that pES cells do not contain paternal imprinted genes, some of which suppress tumors, Cibelli said researchers now need to "look at studies of imprinted genes and pay attention to the ones that are correlated with tumor formation and see how they are expressed."Cathy Tran ctran@the-scientist.comLinks within this article:K. Kim et al., "Histocompatible Embryonic Stem Cells by Parthenogenesis," Science Express, Nov. 14, 2006 http://www.sciencemag.org/cgi/content/abstract/1133542Kent Vrana http://fred.psu.edu/ds/retrieve/fred/investigator/kev10K. Vrana et al., "Nonhuman primate parthenogenetic stem cells," Proc Natl Acad Sci, 100: 11911-11916, 2003 PM_ID: 11823632George Daley http://daley.med.harvard.edu/A. Harding, "Harvard has human cloning plans," The Scientist, Oct. 15, 2004 http://www.the-scientist.com/article/display/22452/P. Hoglund et al., Host MHC class I gene control of NK-cell specificity in the mouse, Immunol Rev, 155:11-28, 1997 PM_ID: 9059879Kitai Kim http://daley.med.harvard.edu/lab_people.htmB. Maher, "The Stem Cell-Cloning Plot Thickens," The Scientist, Feb. 18, 2002 http://www.the-scientist.com/article/display/12870/Jose Cibelli http://www.canr.msu.edu/dept/ans/community/people/cibelli_jose.htmlA. McCook, "Stem cells: Ethics before science" (Blog), The Scientist, March 28, 2006 http://www.the-scientist.com/blog/display/23251/Azim Surani http://www.gurdon.cam.ac.uk/phd/groups/surani.html
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform